Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
MORRISTOWN, N.J., Oct. 26, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter ended September 30, 2017, after the market close on Tuesday, November 7, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Tuesday, November 7 | |
| Time: | 4:30 PM ET | |
| Toll free (U.S.): | 888-599-8667 | |
| International: | 719-325-4793 | |
| Conference ID: | 8272424 | |
| Webcast: | http://public.viavid.com/index.php?id=126501 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Neurology and Pain, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
